The decision making in the Czech nephrology offices depends on the local common practice which is likely to be heterogenous. In other words, the same patient would be indicated to different therapy and regimen at different sites. To date, the practices and treatment paths have not been described. The aim of the present epidemiological research is to characterize the population of CKD patients at the point of treatment choice and to outline the motivation of nephrologist to initiate particular therapy.
This is epidemiological (observational) cross-sectional survey. Data for the research will be obtained from clinical records and patient´s questionnaires and transcribed into electronic case report forms (eCRF) by physician anonymized using subject ID. This observational research will not impose any additional procedures, assessments, or changes in addition to the routine management of subjects. The research does not aim to follow treatment with a single medicinal product. The management of patients will be described in general terms. Names of active substances will be collected rather than the names of individual products.
Study Type
OBSERVATIONAL
Enrollment
1,200
FMC Nemocnice Mělník
Mělník, Central Bohemia, Czechia
RECRUITINGFMC Sokolov
Sokolov, Karlovarský kraj, Czechia
RECRUITINGNemocnice Havlíčkův Brod
Havlíčkův Brod, Kraj Vysočina, Czechia
RECRUITINGSociodemographic parameters
age, gender, ethnicity, health insurance company, education, marital status and cohabitation, employment status/disability, type of employment
Time frame: through study completion, an average of 3 months
Medical history and anthropometry
BMI (in kg/m\^2)
Time frame: through study completion, an average of 3 months
Medical history and anthropometry
blood pressure (systolic/diastolic, in mmHg)
Time frame: through study completion, an average of 3 months
Medical history and anthropometry
time since CKD diagnosis (in years), time since stage 4 CKD (in years), previous referral to nephrology (in years)
Time frame: through study completion, an average of 3 months
Medical history and anthropometry
smoking, abusus
Time frame: through study completion, an average of 3 months
Medical history and anthropometry
aetiology of CKD, comorbidities, current pharmacotherapy
Time frame: through study completion, an average of 3 months
Laboratory parameters
albumin (in g/l)
Time frame: through study completion, an average of 3 months
Laboratory parameters
glycaemia (in mmol/l)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Nemocnice Jihlava
Jihlava, Kraj Vysočina, Czechia
RECRUITINGThetis Seirenia Brno
Brno, South Moravian, Czechia
RECRUITINGTime frame: through study completion, an average of 3 months
Laboratory parameters
CRP (in mg/l)
Time frame: through study completion, an average of 3 months
Laboratory parameters
serum creatinine (in μmol/l)
Time frame: through study completion, an average of 3 months
Laboratory parameters
serum calcium (in mmol/l)
Time frame: through study completion, an average of 3 months
Laboratory parameters
LDL and HDL cholesterol (in mmol/l)
Time frame: through study completion, an average of 3 months
Laboratory parameters
serum urea (in mmol/l)
Time frame: through study completion, an average of 3 months
Laboratory parameters
plasma potassium (in mmol/l)
Time frame: through study completion, an average of 3 months
Laboratory parameters
serum PTH (pmol/l)
Time frame: through study completion, an average of 3 months
Laboratory parameters
albuminuria (in mg/l)
Time frame: through study completion, an average of 3 months
Laboratory parameters
serum phosphorus (mmol/l)
Time frame: through study completion, an average of 3 months
Laboratory parameters
haematuria (erythrocytes/μl)
Time frame: through study completion, an average of 3 months
Laboratory parameters
urine creatinine (mmol/l)
Time frame: through study completion, an average of 3 months
Laboratory parameters
blood count - WBC (10\^9/l)
Time frame: through study completion, an average of 3 months
Laboratory parameters
blood count - RBC (10\^12/l)
Time frame: through study completion, an average of 3 months
Laboratory parameters
blood count - MCV (fl)
Time frame: through study completion, an average of 3 months
Laboratory parameters
blood count - MCHC (g/l)
Time frame: through study completion, an average of 3 months
Laboratory parameters
blood count - HCT
Time frame: through study completion, an average of 3 months
Laboratory parameters
blood count - HGB (g/l)
Time frame: through study completion, an average of 3 months
Laboratory parameters
blood count - PLT (10\^9/l)
Time frame: through study completion, an average of 3 months
Laboratory parameters
blood count - RDW (%)
Time frame: through study completion, an average of 3 months
Prognosis
Bansal score (min. 0, max. 17, higher score means the worse prognosis)
Time frame: through study completion, an average of 3 months
Functional status/frailty/performance
Clinical frailty scale (min. 1, max. 9, higher score means higher frailty)
Time frame: through study completion, an average of 3 months
Nutrition
nutritional status (Full MNA assessment), ketoanalogues, salt intake, protein intake, nutritional education (flyers, consultations etc.), attitude/future adherence to prescribed dietary restrictions
Time frame: through study completion, an average of 3 months
Decision of future management
Choice of future management (conservative management, conservative management with ketoanalogues, dialysis)
Time frame: through study completion, an average of 3 months
Physician attitude to the choice of therapy + reasons
Physician motivation/reasons for treatment choices
Time frame: through study completion, an average of 3 months
Patient attitude to the choice of therapy + reasons
Patient motivation/reasons for treatment choices
Time frame: through study completion, an average of 3 months